The short answer
Pancreatin preparations covered by the label may reduce acarbose’s effect and should not be taken at the same time. The label does not provide a proven number of hours that makes the combination effective.
What this answer covers
Oral pancreatin preparations with carbohydrate-splitting enzymes such as amylase; enzyme composition matters.
- Supplement or preparation
- Pancreatin
- Medication ingredient
- acarbose
The exact label names this product
Acarbose’s label specifically warns that digestive-enzyme preparations containing carbohydrate-splitting enzymes such as pancreatin may reduce its effect and should not be taken concomitantly.
Therapeutic effect is not blood exposure
Acarbose acts locally in the intestine, with very little absorbed as active drug. The label warning supports possible loss of intestinal effectiveness, not a quantified fall in blood concentrations.
The exact preparation matters
Pancreatin products contain differing digestive-enzyme activities. The label concern specifically includes carbohydrate-splitting enzymes; the product name alone cannot quantify the effect.
Resolve the schedule with the prescriber
Ask the pharmacist or prescriber to reconcile the two products with acarbose’s meal-start instructions. Do not invent a spacing interval or move acarbose away from meals on your own. Do not stop prescribed enzyme replacement without a treatment plan.
Evidence and practical considerations
Absorption & effectiveness
Current acarbose label names the preparation as potentially reducing therapeutic effect; no quantified systemic absorption loss.
- Exact scope
- Oral pancreatin preparations with carbohydrate-splitting enzymes such as amylase; enzyme composition matters. with Oral acarbose RxCUI16681 IN; conventional tablets, local intestinal action.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No arbitrary interval, systemic-exposure inference or unmeasured exact event rate.
Factors that may matter: Preparation; Meal timing; Dose; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral acarbose
Local intestinal carbohydrate-digestion inhibition; less than2% absorbed as active drug. Alone should not cause hypoglycemia; insulin/sulfonylurea co-use can increase risk. Oral glucose, not sucrose, for appropriate mild-to-moderate lows. Charcoal adsorbents and carbohydrate-splitting enzymes may reduce effect and should not be taken concomitantly.
How this applies: Exact conventional oral acarbose; controlled-release combination products distinguished.
General warnings do not establish each botanical interaction or arbitrary timing gap. Low systemic absorption is expected, not proof of treatment failure.
Research assessment: · Open full citations ↗
Timing & monitoring
Current acarbose label advises against concomitant use of the covered preparation; no validated hour-based interval supplied.
- Exact scope
- Oral pancreatin preparations with carbohydrate-splitting enzymes such as amylase; enzyme composition matters. with Oral acarbose RxCUI16681 IN; conventional tablets, local intestinal action.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No arbitrary interval, systemic-exposure inference or unmeasured exact event rate.
Factors that may matter: Preparation; Meal timing; Dose; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral acarbose
Local intestinal carbohydrate-digestion inhibition; less than2% absorbed as active drug. Alone should not cause hypoglycemia; insulin/sulfonylurea co-use can increase risk. Oral glucose, not sucrose, for appropriate mild-to-moderate lows. Charcoal adsorbents and carbohydrate-splitting enzymes may reduce effect and should not be taken concomitantly.
How this applies: Exact conventional oral acarbose; controlled-release combination products distinguished.
General warnings do not establish each botanical interaction or arbitrary timing gap. Low systemic absorption is expected, not proof of treatment failure.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact acarbose article distinguishing local action, rescue sugar, formulation and original clinical findings. | |
| Research summary published |
Article revision: 2ce014fcc05f4899
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.